


How similar is this cluster to the other clusters?

Genes in the cluster along with the pathways as annotated by experts


Expert Annotation		
Treatment	Pathway	Regulation Type
PRKCZ.WT.1	Canonical PKC	Activator
PRKCZ.WT.2	Canonical PKC	Activator
PRKCZ.K281R	Canonical PKC	Inhibitor




Top 5 genes negatively correlated to the cluster

Expert Annotation				
Treatment	Pathway	Regulation Type	Mean Correlation	Standard Deviation
WWTR1.WT	Canonical Hippo	Inhibitor	-0.50	0.10
STK11.WT.1	Canonical TOR	Inhibitor	-0.43	0.06
NFKB1.WT	Canonical NFkB	Inhibitor	-0.40	0.14
TGFB1.WT	Canonical TGFbeta	Activator	-0.35	0.11
DIABLO.WT	Canonical Apoptosis	Inhibitor	-0.33	0.04

What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a feature z-score across genes in the cluster) Black means no feature is available in the category



Which individual morphological features are distinguishing in the cluster relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.



How strongly are genes within the cluster correlated?
















Plate : 41744 - Genes in the Cluster (Channels are sorted based on their dominance in the grid plot)



























Compound IDs and common names (where available); blue/red colored box means the matching compound is positively/negatively correlated with the cluster	Chemical structure	Mean pairwise replicates correlation of the compound signature (95th DMSO replicate correlation is 0.54)	Mean $\pm$ standard deviation correlation between compound and each gene in cluster; Tables contain data for individual genes	Mean compound rank when scored against genes in cluster using L1000 profiling $\pm$ standard deviation; Tables contain data for individual genes	How similar is the compound signature to the gene clusters in this experiment? (Yellow and red lines correspond to top/bottom 1st and 5th percentile DMSO correlation to all the genes)	Common distinguishing feature categories in the compound and genes in the cluster relative to the untreated samples	Distinguishing individual features for the compound relative to untreated samples. Black means a mismatch; i.e. active (= high z-score in magnitude) in the compound, and either inactive (= small z-score in magnitude) or oppositely active in the gene cluster	Number of PubChem assays in which the compound was tested; assays in which the compound was active are itemized								
BRD-K28901743-001-05-3 ZINC01748812 AC1LTAWC MLS000552933 ZINC1748812 CCG-15676 STL331422 BAS 00558059 SMR000175471 ST50181975 PubChem CID : 1555494		NA (in 1 replicates)	<div>0.56 <math>\pm</math> 0.14</div> <table><thead><tr><th>Treatment</th><th>Score</th></tr></thead><tbody><tr><td>PRKCZ.K281R</td><td>0.70</td></tr><tr><td>PRKCZ.WT.1</td><td>0.30</td></tr><tr><td>PRKCZ.WT.2</td><td>0.55</td></tr></tbody></table>	Treatment	Score	PRKCZ.K281R	0.70	PRKCZ.WT.1	0.30	PRKCZ.WT.2	0.55	NA				Total number of assays tested in: 626. Active in the following assays: <ul style="list-style-type: none"><li>Screen for Chemicals that Extend Yeast Lifespan (AID 775)</li><li>uHTS identification of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463190)</li><li>Single concentration confirmation of small molecule inhibitors of tim10-1 yeast via a luminescent assay (AID 463213)</li><li>Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the fructose-bisphosphate aldolase (FBA) of M. tuberculosis (AID 588726)</li><li>Fluorescence Intensity-based biochemical primary high throughput screening assay to identify activators of kallikrein-7 (K7) zymogen (AID 652039)</li><li>Fluorescence Intensity-based biochemical primary high throughput confirmation assay to identify activators of kallikrein-7 (K7) zymogen (AID 680949)</li><li>Counter-screen for activators of kallikrein-7 (K7) zymogen: Fluorescence intensity-based biochemical high throughput counter-screen assay for activators that optically interfere with measurement of EDANS-DABCYL fluorescence (AID 686952)</li></ul>
Treatment	Score															
PRKCZ.K281R	0.70															
PRKCZ.WT.1	0.30															
PRKCZ.WT.2	0.55															




<div>BRD-K19061245-001-01-9</div> <div>PubChem CID : 54646112</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div><div>0.52 ± 0.07</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.49</div><div>PRKQZ_WT.1</div><div>0.60</div><div>PRKQZ_WT.2</div><div>0.48</div></div></div> <div><div>0.903 ± 0.104</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.902</div><div>PRKQZ_WT.1</div><div>0.900</div><div>PRKQZ_WT.2</div><div>0.897</div></div></div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 39.</div>
<div>BRD-K93020827-001-05-1</div> <div>ZINC00816378</div> <div>BAS 09615699</div> <div>SMR000015176</div> <div>MLS000076577</div> <div>AC1LCQ1V</div> <div>MLS001385186</div> <div>HMS2396B23</div> <div>ZINC816378</div> <div>CCG-41713</div> <div>STK775374</div> <div>ST4102952</div> <div>PubChem CID : 654198</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div><div>0.50 ± 0.14</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.46</div><div>PRKQZ_WT.1</div><div>0.58</div><div>PRKQZ_WT.2</div><div>0.47</div></div></div> <div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 783. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region (AID 589)</li><li>qHTS Assay for Spectroscopic Profiling in A350 Spectral Region (AID 590)</li><li>Profiling the NIH Molecular Libraries Small Molecule Repository: Autofluorescence at 339/460 nm (AID 709)</li><li>Screening for Modulators of Post-Golgi Transport, Control Strain (AID 738)</li><li>CYP2C9 Assay (AID 777)</li><li>qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region (AID 923)</li><li>A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (AID 624297)</li><li>Counterscreen of compound fluorescence effects on High-throughput multiplex microsphere screening for inhibitors of toxin protease (AID 624483)</li><li>Luminescence-based cell-based high throughput confirmation assay for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2) (AID 651613)</li><li>Counterscreen for inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2): Luminescence-based cell-based high throughput assay to identify inverse agonists of the Steroidogenic Factor 1 Nuclear Receptor (SF1; NR5A1) (AID 651614)</li><li>qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT (AID 686978)</li><li>qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT (AID 686979)</li></ul></div>
<div>BRD-K57239091-001-05-0</div> <div>ZINC04338445</div> <div>AC1OI4H0</div> <div>MLS000624384</div> <div>HMS2725H19</div> <div>ZINC4338445</div> <div>SMR000323687</div> <div>PB133693860</div> <div>F1850-0005</div> <div>PubChem CID : 7197007</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div><div>0.50 ± 0.08</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.43</div><div>PRKQZ_WT.1</div><div>0.59</div><div>PRKQZ_WT.2</div><div>0.48</div></div></div> <div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 614. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>Aqueous Solubility from MLSMR Stock Solutions (AID 1996)</li><li>Counterscreen for inhibitors of 5-mCpG-binding domain protein 2 (MBD2): TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of binding of ubiquitin-like with PHD and ring finger domains 1 (UHRF1) to methylated oligonucleotide (AID 687016)</li></ul></div>
<div>BRD-K19608696-001-04-5</div> <div>MLS001121487</div> <div>HMS1859H04</div> <div>HMS2253I17</div> <div>ZINC6818267</div> <div>ZINC06818267</div> <div>SMR000626594</div> <div>EI57-5383</div> <div>PubChem CID : 16017323</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div><div>0.50 ± 0.07</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.51</div><div>PRKQZ_WT.1</div><div>0.54</div><div>PRKQZ_WT.2</div><div>0.42</div></div></div> <div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 508. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53s Null Cells at the Nonpermissive Temperature (AID 902)</li><li>qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature (AID 904)</li><li>A screen for compounds that inhibit cell wall-associated teichoic acid synthesis in Staphylococcus aureus (AID 463173)</li><li>qHTS Assay for the Inhibitors of Schistosoma mansoni Peroxiredoxins (AID 485364)</li><li>qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)</li><li>Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA) (AID 651718)</li><li>Absorbance-based biochemical high throughput confirmation assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA) (AID 651822)</li></ul></div>
<div>BRD-K60865828-001-05-7</div> <div>BAS 05022416</div> <div>AC1LL2O5</div> <div>MLS001211773</div> <div>HMS1615G11</div> <div>HMS2838A09</div> <div>ZINC789744</div> <div>STK090735</div> <div>ZINC00789744</div> <div>SMR000523157</div> <div>VU0417912-1</div> <div>PubChem CID : 1077764</div>	<div></div>	<div>0.55 (in 4 replicates)</div>	<div><div>0.49 ± 0.04</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.53</div><div>PRKQZ_WT.1</div><div>0.45</div><div>PRKQZ_WT.2</div><div>0.49</div></div></div> <div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 470. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3 (AID 692410)</li><li>Confirmation assay for identification of compounds that inhibit the two-pore domain potassium channel KCNK3 [Primary Screening] (AID 651638)</li><li>qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)</li></ul></div>
<div>BRD-K09787095-001-01-2</div> <div>PubChem CID : 54646572</div>	<div></div>	<div>0.80 (in 4 replicates)</div>	<div><div>0.49 ± 0.07</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.56</div><div>PRKQZ_WT.1</div><div>0.49</div><div>PRKQZ_WT.2</div><div>0.43</div></div></div> <div>0.303 ± 0.319</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 36.</div>
<div>BRD-K94843767-001-01-6</div> <div>PubChem CID : 54646105</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div><div>0.48 ± 0.04</div><div><div>Treatment</div><div>Score</div><div>PRKQZ_K20H1</div><div>0.52</div><div>PRKQZ_WT.1</div><div>0.48</div><div>PRKQZ_WT.2</div><div>0.41</div></div></div> <div>0.289 ± 0.296</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 41.</div>



<div>BRD-K47430271-001-05-0</div> <div>SMR000184928</div> <div>Ambcb5227425</div> <div>AC1NX317</div> <div>HMS2509F11</div> <div>LS-38042</div> <div>119034-11-6</div> <div>PubChem CID : 5719122</div>	<div></div>	<div>0.61 (in 4 replicates)</div>	<div>0.48 ± 0.07</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>PRK CZ_K20H1</td><td>-0.54</td></tr><tr><td>PRK CZ_WT.1</td><td>-0.39</td></tr><tr><td>PRK CZ_WT.2</td><td>-0.50</td></tr></table>	Treatment	Score	PRK CZ_K20H1	-0.54	PRK CZ_WT.1	-0.39	PRK CZ_WT.2	-0.50	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 632. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity (AID 2546)</li><li>qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)</li><li>qHTS Assay for Inhibitors of Hepatitis C Virus (HCV) (AID 651820)</li></ul></div>
Treatment	Score															
PRK CZ_K20H1	-0.54															
PRK CZ_WT.1	-0.39															
PRK CZ_WT.2	-0.50															
<div>BRD-K27473490-001-05-9</div> <div>ASN 05115081</div> <div>SMR000118756</div> <div>AC1MLIEB</div> <div>MLS000121325</div> <div>MLS002534460</div> <div>HMS2325M18</div> <div>ZINC8676962</div> <div>ZINC08676962</div> <div>PubChem CID : 3195163</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div>0.46 ± 0.08</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>PRK CZ_K20H1</td><td>-0.57</td></tr><tr><td>PRK CZ_WT.1</td><td>-0.37</td></tr><tr><td>PRK CZ_WT.2</td><td>-0.40</td></tr></table>	Treatment	Score	PRK CZ_K20H1	-0.57	PRK CZ_WT.1	-0.37	PRK CZ_WT.2	-0.40	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 670. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode) (AID 624417)</li></ul></div>
Treatment	Score															
PRK CZ_K20H1	-0.57															
PRK CZ_WT.1	-0.37															
PRK CZ_WT.2	-0.40															
<div>BRD-K48818351-001-01-7</div> <div>PubChem CID : 54641364</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div>-0.61 ± 0.03</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>PRK CZ_K20H1</td><td>-0.61</td></tr><tr><td>PRK CZ_WT.1</td><td>-0.65</td></tr><tr><td>PRK CZ_WT.2</td><td>-0.58</td></tr></table>	Treatment	Score	PRK CZ_K20H1	-0.61	PRK CZ_WT.1	-0.65	PRK CZ_WT.2	-0.58	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 37.</div>
Treatment	Score															
PRK CZ_K20H1	-0.61															
PRK CZ_WT.1	-0.65															
PRK CZ_WT.2	-0.58															
<div>BRD-K69073107-001-01-0</div> <div>MLS003650002</div> <div>SMR00239547</div> <div>PubChem CID : 53382665</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div>-0.60 ± 0.08</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>PRK CZ_K20H1</td><td>-0.60</td></tr><tr><td>PRK CZ_WT.1</td><td>-0.59</td></tr><tr><td>PRK CZ_WT.2</td><td>-0.53</td></tr></table>	Treatment	Score	PRK CZ_K20H1	-0.60	PRK CZ_WT.1	-0.59	PRK CZ_WT.2	-0.53	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 132.</div>
Treatment	Score															
PRK CZ_K20H1	-0.60															
PRK CZ_WT.1	-0.59															
PRK CZ_WT.2	-0.53															
<div>BRD-K05680206-001-06-8</div> <div>ST51024277</div> <div>AC1LNZAM</div> <div>SMR000114553</div> <div>MLS000550223</div> <div>HMS2353E22</div> <div>ZINC984086</div> <div>ZINC00984086</div> <div>PubChem CID : 1211462</div>	<div></div>	<div>0.87 (in 2 replicates)</div>	<div>-0.58 ± 0.07</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>PRK CZ_K20H1</td><td>-0.59</td></tr><tr><td>PRK CZ_WT.1</td><td>-0.64</td></tr><tr><td>PRK CZ_WT.2</td><td>-0.50</td></tr></table>	Treatment	Score	PRK CZ_K20H1	-0.59	PRK CZ_WT.1	-0.64	PRK CZ_WT.2	-0.50	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 679. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>Primary cell-based high throughput screening assay to measure STAT1 activation (AID 932)</li><li>qHTS Assay for Enhancers of SMN2 Splice Variant Expression (AID 1458)</li><li>MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators (AID 1814)</li><li>qHTS Assay for Modulators of miRNAs and/or Inhibitors of miR-21 (AID 2289)</li><li>Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)</li><li>A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)</li><li>Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line (AID 463079)</li><li>qHTS Assay for Rab9 Promoter Activators (AID 485297)</li><li>qHTS Assay for NPC1 Promoter Activators (AID 485313)</li><li>Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01.Activator.SinglePoint.HTS.Activity (AID 504408)</li><li>MTTF: Counter assay: A375 proliferation Measured in Cell-Based System Using Plate Reader - 2084-03.Inhibitor.Dose.CherryPick.Activity.Set2 (AID 540335)</li><li>MTTF: Counter assay: A375 proliferation Measured in Cell-Based System Using Plate Reader - 2084-03.Inhibitor.Dose.DryPowder.Activity (AID 540346)</li><li>qHTS profiling assay for firefly luciferase - inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)</li><li>Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01.Inhibitor.SinglePoint.HTS.Activity (AID 602393)</li><li>uHTS identification of small molecule inhibitors of the mitochondrial permeability transition pore via an absorbance assay (AID 602449)</li><li>qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression (AID 624202)</li><li>Single concentration confirmation of qHTS inhibitor hits of the mitochondrial permeability transition pore via a fluorescent based assay (AID 624504)</li><li>Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01.Activator.SinglePoint.HTS.Activity (AID 743398)</li><li>Wnt/Beta-catenin HTS Measured in Cell-Based System Using Plate Reader - 2161-01.Activator.Dose.CherryPick.Activity (AID 1053144)</li></ul></div>
Treatment	Score															
PRK CZ_K20H1	-0.59															
PRK CZ_WT.1	-0.64															
PRK CZ_WT.2	-0.50															
<div>BRD-K08606983-001-05-1</div> <div>STK138991</div> <div>AC1OBPFE</div> <div>SMR000259826</div> <div>MLS000390788</div> <div>ZINC15989497</div> <div>T0500-2826</div> <div>PubChem CID : 6900173</div>	<div></div>	<div>NA (in 1 replicates)</div>	<div>-0.57 ± 0.08</div> <table><tr><th>Treatment</th><th>Score</th></tr><tr><td>PRK CZ_K20H1</td><td>-0.60</td></tr><tr><td>PRK CZ_WT.1</td><td>-0.50</td></tr><tr><td>PRK CZ_WT.2</td><td>-0.57</td></tr></table>	Treatment	Score	PRK CZ_K20H1	-0.60	PRK CZ_WT.1	-0.50	PRK CZ_WT.2	-0.57	<div>NA</div>	<div></div>	<div></div>	<div></div>	<div>Total number of assays tested in: 631. Active in the following assays:</div> <div><ul style="list-style-type: none"><li>Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)</li><li>A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)</li><li>VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity (AID 2546)</li><li>qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)</li><li>uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay (AID 493098)</li><li>qHTS profiling assay for firefly luciferase - inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)</li><li>uHTS identification of small molecule modulators of myocardial damage (AID 588392)</li><li>Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human trace amine associated receptor 1 (TAAR1) (AID 624466)</li><li>uHTS identification of inhibitors of cullin neddylation in a TR-FRET assay (AID 651699)</li></ul></div>
Treatment	Score															
PRK CZ_K20H1	-0.60															
PRK CZ_WT.1	-0.50															
PRK CZ_WT.2	-0.57															






BRD-K01990668-001-06-6  
SMR000017492  
ZINC00426457  
AC1LD48Q  
MLS000077450  
MLS000100847  
AC1Q28Q2  
HMS1417B06  
HMS2274A08  
ZINC426457  
STK859226  
PubChem CID : 660991



0.77 (in 3 replicates)


-0.56 ± 0.06  
Treatment Score  
PRCCE\_K20H1 -0.03  
PRCCE\_WF1 -0.32  
PRCCE\_WF2 -0.32

NA



- Total number of assays tested in: 697. Active in the following assays:
- CYP2C9 Assay (AID 777)
  - High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen (AID 1239)
  - qHTS Assay for Enhancers of SMN2 Splice Variant Expression (AID 1458)
  - MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators (AID 1814)
  - Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
  - A qHTS for Small Molecule Inhibitors of Shiga Toxin (AID 2315)
  - uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SEN6) (AID 2599)
  - HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress (AID 2732)
  - uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SEN7) (AID 434973)
  - qHTS Assay for Rab9 Promoter Activators (AID 485297)
  - qHTS Assay for NPC1 Promoter Activators (AID 485313)
  - Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01 Activator.SinglePoint.HTS.Activity (AID 504408)
  - qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 (AID 504466)
  - Primary qHTS for delayed death inhibitors of the malarial parasite plasmodium, 96 hour incubation (AID 504834)
  - MTF Measured in Cell-Based System Using Plate Reader - 2084-01 Activator.SinglePoint.HTS.Activity (AID 588334)
  - qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project) (AID 588342)
  - Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01 Inhibitor.SinglePoint.HTS.Activity (AID 602393)
  - Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM) (AID 652017)
  - Counterscreen for activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM); Luminescence-based cell-based high throughput screening assay to identify non-selective compounds using the VP16 reporter assay (AID 686939)
  - qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen (AID 720504)




BRD-K08564028-001-04-2  
F1602-0395  
AC1M21WZ  
MLS000724735  
HMS2255H24  
ZINC2688545  
ZINC02688545  
SMR000237570  
PubChem CID : 2135408



NA (in 1 replicates)


-0.55 ± 0.11  
Treatment Score  
PRCCE\_K20H1 -0.32  
PRCCE\_WF1 -0.07  
PRCCE\_WF2 -0.45

NA



- Total number of assays tested in: 648. Active in the following assays:
- Activator for delta FosB/delta FosB homodimer Measured in Biochemical System Using Plate Reader - 2072-01 Activator.SinglePoint.HTS.Activity (AID 493131)
  - uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay (AID 588458)
  - uHTS luminescent assay for identification of compounds that enhance the survival of human induced pluripotent stem cells when cultured as single cells (AID 602274)
  - Dose response confirmation of uHTS hits that enhance the survival of human induced pluripotent stem cells when cultured as single cells in a luminescent assay (AID 623861)
  - Dose response confirmation of uHTS hits that enhance the survival of human induced pluripotent stem cells when cultured as single cells in a fluorescent-based, imaging assay (AID 624145)




BRD-K76407984-001-01-9  
PubChem CID : 54641072



NA (in 1 replicates)


-0.55 ± 0.09  
Treatment Score  
PRCCE\_K20H1 -0.45  
PRCCE\_WF1 -0.51  
PRCCE\_WF2 -0.48

NA



Total number of assays tested in: 38.




BRD-K52473712-001-04-2  
MLS000762753  
STK592482  
ZINC33887359  
SMR000439749  
PubChem CID : 9631393



NA (in 1 replicates)

-0.54 ± 0.02  
Treatment Score  
PRCCE\_K20H1 -0.56  
PRCCE\_WF1 -0.35  
PRCCE\_WF2 -0.52



NA



Total number of assays tested in: 521.



Treatment	Score
PRKCZ.K281R	-0.53
PRKCZ.WT.1	-0.61
PRKCZ.WT.2	-0.49

[illegible]

total number of assays tested in: 698. Active in the following assays:

- Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Primary Biochemical (AID 1456)
- Primary biochemical high throughput screening assay to identify inhibitors of VIM-2 metallo-beta-lactamase (AID 1527)
- Epi-absorbance primary biochemical high throughput screening assay to identify inhibitors of TMP-1 metallo-beta-lactamase (AID 1550)
- Identification of Novel Modulators of Cl- dependent Transport Process via HTS: Retesting of KC23 cells with Onabot (AID 1717)
- Epi-absorbance-based confirmation biochemical high throughput screening assay to identify selective inhibitors of VIM-2 metallo-beta-lactamase (AID 1860)
- Fluorescence-based primary cell-based high throughput screening assay to identify antagonists of the G-protein coupled receptor 7 (GPR7). (AID 1861)
- qHTS for Antagonists of gsp, the Eukaryotic G-protein Receptor Responsible for Filovirus Dysplasia/McCune-Albright Syndrome: qHTS (AID 62428)
- Fluorescence-based biochemical primary high throughput screening assay to identify molecules that bind rCAG) RNA repeats (AID 651821)
- Fluorescence-based biochemical high throughput confirmation assay to identify molecules that bind rCAG) RNA repeats (AID 652065)
- Counter screen for molecules that bind rCAG RNA repeats: fluorescence-based biochemical high throughput screening assay to identify RNA-based gCAG/3'GTC) To-PRO-1 dye complex (AID 652068)

Treatment	Score
PRKCZ.K281R	-0.57
PRKCZ.WT.1	-0.56
PRKCZ.WT.2	-0.49

Risk Factor	Mean Change in Risk
Age	0.00
Sex	-0.25
Education	-0.15
Income	-0.10
Employment	-0.15
Health Insurance	-0.10
Chronic Conditions	-0.15
Mental Health	-0.10
Substance Use	-0.15
Social Support	-0.10
Family History	-0.15
Genetic Factors	-0.10
Environmental Factors	-0.15
Lifestyle Factors	-0.10
Health Services	-0.15

